Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells

por Milone, M R, Pucci, B, Bruzzese, F, Carbone, C, Piro, G, Costantini, S, Capone, F, Leone, A, Di Gennaro, E, Caraglia, M, Budillon, A
Publicado 2013

Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells

por Milone, M R, Pucci, B, Bruzzese, F, Carbone, C, Piro, G, Costantini, S, Capone, F, Leone, A, Di Gennaro, E, Caraglia, M, Budillon, A
Publicado 2014

The miR-27a-calreticulin axis affects drug-induced immunogenic cell death in human colorectal cancer cells

por Colangelo, T, Polcaro, G, Ziccardi, P, Muccillo, L, Galgani, M, Pucci, B, Rita Milone, M, Budillon, A, Santopaolo, M, Mazzoccoli, G, Matarese, G, Sabatino, L, Colantuoni, V
Publicado 2016

Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways

por Bruzzese, F, Pucci, B, Milone, M R, Ciardiello, C, Franco, R, Chianese, M I, Rocco, M, Di Gennaro, E, Leone, A, Luciano, A, Arra, C, Santini, D, Caraglia, M, Budillon, A
Publicado 2013

Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancer

por Colangelo, T, Polcaro, G, Ziccardi, P, Pucci, B, Muccillo, L, Galgani, M, Fucci, A, Milone, M R, Budillon, A, Santopaolo, M, Votino, C, Pancione, M, Piepoli, A, Mazzoccoli, G, Binaschi, M, Bigioni, M, Maggi, C A, Fassan, M, Laudanna, C, Matarese, G, Sabatino, L, Colantuoni, V
Publicado 2016